Filters

EPHB3/Eph receptor B3 Antibody, Cy3 Conjugated

EPHB3/Eph receptor B3 Antibody, Cy3 Conjugated size: 0.1ml 350

Price 350
Size 0.1ml
Long name Cy3 Conjugated, EPHB3/Eph receptor B3 Antibody
CategoryConjugated Primary Antibodies
Conjugationcy3 conjugation kit
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenEPHB3/Eph receptor B3
SpecificityThis is a highly specific antibody against EPHB3/Eph receptor B3
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
Subcellular locationExtracellular
SourceKLH conjugated synthetic peptide derived from human EPHB3/Eph receptor B3
Tested applications IF(IHC-P), FCM
Recommended dilutions IF(IHC-P)(1:50-200), FCM(1:20-100)
Crossreactivity Mouse, Rat, Human
Crossreactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Antigen background EphA2 (Eck), EphA3 (Hek4), EphA4 (Hek8), EphA5 (Hek7), EphA6 (Hek12), EphA7 (Hek11/MDK1), EphA8 (Hek3), EphB1 (Hek6), EphB2 (Hek5), EphB3 (Cek10, EphB4 (Htk), EphB5 (Hek9) and EphB6 (Mep), Hek2), In addition, Ligands for Eph receptors include ephrin-A4 (LERK-4) which binds EphA3 and EphB1, The Eph subfamily receptors of human origin (and their murine/avian homologs) include EphA1 (Eph), While the biological activities of these receptors have yet to be determined, ephrin-A2 (ELF-1) has been described as the ligand for EphA4, ephrin-A3 (Ehk1-L) as the ligand for EphA5 and ephrin-B2 (Htk-L) as the ligand for EphB4 (Htk) (4â, there is increasing evidence that they are involved in central nervous system function and in development (1â, &euro, &euro, &euro, &ldquo, &ldquo, &ldquo, 3), 3), 7), The Eph subfamily represents the largest group of receptor protein tyrosine kinases identified to date (1â
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission512, 550nm/570, 615nm
Synonyms Hek2 Tyro6
Properties 1 of the EPHB3/Eph receptor B3 Antibody, Conjugated can be used in flow cytometry but typically shows lower fluorescence intensity comparable to that of PE or APC, Cy3 antibodies are excited by the 488-nanometer wave of an argon laser and the 633-nanometer line of a helium-neon diode laser, This Bioss Primary Conjugated Antibodies antibody is well suited for fluorescent microscopy, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
Description 2 or 3 and , However, In this sense, When such chemical-signals couple or bind to a receptor, a change in the electrical-activity of a cell, acetylcholine, am olfactory receptor is a protein-molecule that recognizes and responds to , an acetylcholine-receptor recognizes and responds to its endogenous-ligand, chemokinesor cytokines e, e, sometimes in pharmacology, such as enzymes, the term is also used to include other proteins that are drug-targets, they cause some form of cellular/tissue-response, transporters and ion-channels, The receptors are ligand binding factors of type 1, endogenous-chemical signals, g, g, protein-molecules , that receive chemical-signals from outside a cell
Gene targetEPHB3/Eph receptor B3 Conjugated
Short name Conjugated, EPHB3/Eph receptor B3 Antibody
Technique antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelCy3
Alternative name cyanine 3 coupled, EPHB3/Eph receptor B3 (Antibody to)
Alternative techniqueantibodies
Identity 3394
Gene EPHB3
Long gene name EPH receptor B3
Synonyms gene ETK2
Synonyms gene name EphB3
Locus 3q27, 1
Discovery year 1993-12-07
GenBank acession X75208
Entrez gene record 2049
Pubmed identfication 8397371
RefSeq identity NM_004443
Classification Sterile alpha motif domain containing Fibronectin type III domain containing EPH receptors
Havana BLAST/BLAT OTTHUMG00000156710

Subscribe to our Newsletter